Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor dose-ranging placebo-controlled phase 2 study in adults with NASH
NL-OMON47382Phase 2Active, not recruiting
- Sponsor
- Inventiva
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Inventiva. Primary endpoints: Primary efficacy endpoint and Safety assessments. Started Feb 2018; status: active, not recruiting.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON47382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47382.